Real-World Gene Therapy Implementation Shows Promise for Blood Disorders Despite Timeline Challenges
Key Insights
The first real-world study of commercial gene therapy rollout for sickle cell disease (search) and beta thalassemia (search) analyzed 392 U.S. patients, revealing median treatment timelines of 9.8 months for beti-cel and 7.9 months for lovo-cel from enrollment to infusion.
Among enrolled patients, 29% have received treatment to date, with 72% of beti-cel patients and 76% of lovo-cel patients completing therapy within one year of enrollment.
Researchers identified operational factors including insurance approvals, cell collection requirements, and manufacturing capacity as key influences on treatment timelines, with the most variability occurring during patient preparation phases.
The first comprehensive analysis of real-world gene therapy implementation for inherited blood disorders reveals both the promise and operational challenges of delivering these transformative treatments to patients with sickle cell disease (search) and beta thalassemia (search).
Researchers from Genetix Biotherapeutics (search) analyzed data from 392 U.S. patients who enrolled to receive either betibeglogene autotemcel (beti-cel, marketed as Zynteglo) or lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia) between 2022 and 2025. The study, presented at the American Society of Hematology annual meeting, provides the first real-world insights into commercial gene therapy deployment.
Treatment Timeline Analysis
The analysis revealed median treatment timelines of 9.8 months for beti-cel and 7.9 months for lovo-cel from enrollment decision to drug product infusion. Of the 392 enrolled patients, 29% (115) have received treatment to date, with 72% of beti-cel patients and 76% of lovo-cel patients completing therapy within one year of enrollment.
"Gene therapy requires system-level coordination and close collaboration across patients, treatment centers, payers, and manufacturers," said study author Joanne Lager, MD, chief medical officer at Genetix Biotherapeutics (search). "The demand for these one-time durable gene therapies is growing, and we're learning how to deliver treatment more efficiently as we gain more experience."
The most significant variability occurred during the patient preparation phase, with a median time of 4.4 months between enrollment decision and stem cell collection. This period involves medical and financial preparation of patients for therapy.
Manufacturing and Collection Insights
Most patients required only one cell collection procedure for both therapies - 79% for beti-cel and 63% for lovo-cel, consistent with clinical trial experience. However, additional collection cycles significantly impacted timelines, adding approximately 80 days per collection cycle.
Once stem cells were collected, manufacturing, testing, and delivery of the gene therapy drug product to treatment centers took a median of 3.2 months for beti-cel and 3.5 months for lovo-cel.
Learning Curve Benefits
The study revealed operational differences between the two gene therapies that suggest learning curve benefits. The time between FDA approval and first commercial patient enrollment was approximately half as long for lovo-cel compared to beti-cel. Since beti-cel received FDA approval about 16 months before lovo-cel, researchers suggest that early implementation experience with beti-cel better prepared treatment centers for lovo-cel deployment.
Therapeutic Background
Both sickle cell disease (search) and beta thalassemia (search) are inherited disorders affecting hemoglobin in red blood cells. Beta thalassemia results in insufficient functional hemoglobin production, impacting oxygen-carrying capacity and leading to debilitating symptoms and organ damage. Sickle cell disease causes abnormal hemoglobin production, resulting in rigid, sickle-shaped red blood cells that block blood vessels and cause pain and organ damage.
The gene therapies work by collecting patients' own stem cells, manufacturing them to add functional copies of modified genes, and infusing them back into patients to engraft in bone marrow and produce red blood cells with functional hemoglobin. The FDA approved beti-cel for transfusion-dependent beta thalassemia (search) in 2022 and lovo-cel for sickle cell disease (search) in 2023.
Future Improvements
"We've identified areas of opportunity to enhance the treatment journey for patients and providers," said Dr. Lager. "We recognize the importance of delivering our therapies to patients as soon as possible and remain committed to improving the treatment experience."
Researchers identified operational factors including insurance approvals, cell collection requirements, and manufacturing capacity as key influences on treatment timelines. The study noted that insurance coverage for these treatments has continued to expand.
"Demand for our gene therapies continue to build. We are actively working toward ensuring that we have the manufacturing capacity to deliver gene therapy to all patients seeking a path to a cure," said Dr. Lager.
The researchers plan continued process improvements and collaboration with medical centers to share lessons learned and develop best practices for overcoming barriers and increasing efficiency in gene therapy delivery.